Mackenzie Financial
AMRX icon

Mackenzie Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Mackenzie Financial’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181,806
Closed -$2.34M – 1442
2025
Q4 		$2.34M Sell
181,806
-13,998
-7% -$160K ﹤0.01% 812
2025
Q3 		$1.96M Buy
195,804
+9,196
+5% +$82.5K ﹤0.01% 838
2025
Q2 		$1.51M Buy
186,608
+17,778
+11% +$134K ﹤0.01% 894
2025
Q1 		$1.41M Buy
168,830
+156,609
+1,281% +$1.31M ﹤0.01% 881
2024
Q4 		$96.8K Hold
12,221
– – ﹤0.01% 1636
2024
Q3 		$102K Sell
12,221
-9,917
-45% -$77.5K ﹤0.01% 1477
2024
Q2 		$141K Sell
22,138
-848
-4% -$5.38K ﹤0.01% 1400
2024
Q1 		$139K Buy
22,986
+4,803
+26% +$27.1K ﹤0.01% 1398
2023
Q4 		$110K Sell
18,183
-2,936
-14% -$13.1K ﹤0.01% 1400
2023
Q3 		$91.7K Sell
21,119
-6,987
-25% -$26.1K ﹤0.01% 1356
2023
Q2 		$85.7K Hold
28,106
– – ﹤0.01% 1422
2023
Q1 		$39.1K Hold
28,106
– – ﹤0.01% 1456
2022
Q4 		$55.9K Buy
+28,106
New +$63K ﹤0.01% 1343
2020
Q2 		– Sell
-177,878
Closed -$619K – 1010
2020
Q1 		$619K Buy
+177,878
New +$753K ﹤0.01% 769

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Mackenzie Financial's AMRX Position: Q1 2026 in Review

Mackenzie Financial sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 181,806 shares — an estimated $2.34M sold.

Mackenzie Financial first reported a position in AMRX in Q1 2020 and held it in 14 quarters. The position peaked at $2.34M in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Mackenzie Financial reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 181,806 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.34M.
  • Mackenzie Financial first reported a position in Amneal Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Mackenzie Financial's Amneal Pharmaceuticals position peaked at $2.34M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.